Plain-English translation of NCT06142552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called , which is a lab-made clotting factor designed to help people with severe hemophilia A prevent dangerous bleeding episodes. Hemophilia A is a condition where your blood doesn't clot properly because your body doesn't make enough of a natural protein called factor VIII. The medication aims to work longer in your body than older treatments, potentially requiring fewer injections.
Current hemophilia A treatments work well but often require frequent injections and don't last very long in the body. This study is testing whether the new medication can prevent bleeds more effectively and last longer, giving patients more freedom and fewer treatment burdens.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the new medication on a schedule designed to prevent bleeding—either regularly (prevention group) or as needed when bleeds occur (on-demand group). You'll have multiple study visits over about one year where researchers check how well the medication works, how long it stays in your body, and monitor for any side effects. If you need surgery during the trial, the medication will be adjusted to help your blood clot during and after the procedure.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China